Home

Protagonist Therapeutics, Inc. - Common Stock (PTGX)

87.70
+20.66 (30.82%)
NASDAQ · Last Trade: Oct 10th, 3:58 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.chartmill.com
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · October 10, 2025
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · October 10, 2025
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Reportbenzinga.com
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.
Via Benzinga · October 10, 2025
Which stocks are experiencing notable movement on Friday?chartmill.com
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · October 10, 2025
9 Analysts Assess Protagonist Therapeutics: What You Need To Knowbenzinga.com
Via Benzinga · June 3, 2025
5 Analysts Assess Protagonist Therapeutics: What You Need To Knowbenzinga.com
Via Benzinga · October 8, 2025
Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviewsbenzinga.com
Via Benzinga · September 17, 2025
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trialsbenzinga.com
Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.
Via Benzinga · September 17, 2025
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesdaybenzinga.com
Via Benzinga · September 17, 2025
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Fridaybenzinga.com
Via Benzinga · September 12, 2025
What 4 Analyst Ratings Have To Say About Protagonist Therapeuticsbenzinga.com
Via Benzinga · August 7, 2025
Protagonist (PTGX) Q2 Revenue Falls 26%fool.com
Via The Motley Fool · August 7, 2025
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?investors.com
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via Investor's Business Daily · June 30, 2025
PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing some interesting technicals. Here's why.chartmill.com
Interesting Technical Analysis finding for PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX): Indications Suggest NASDAQ:PTGX Could Be on the Verge of a Breakout.
Via Chartmill · May 15, 2025
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Studybenzinga.com
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.
Via Benzinga · May 9, 2025
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Studybenzinga.com
Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.
Via Benzinga · April 10, 2025
Does PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) align with Mark Minervini’s trading strategy?chartmill.com
Should you consider PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) for high growth investing? A fundamental and technical analysis of (NASDAQ:PTGX).
Via Chartmill · April 5, 2025
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?benzinga.com
Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains.
Via Benzinga · March 16, 2025
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · March 11, 2025
Keep an eye on the top gainers and losers in Monday's session.chartmill.com
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Via Chartmill · March 10, 2025
Monday's session: top gainers and loserschartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · March 10, 2025
Let's uncover which stocks are experiencing notable gaps during today's session.chartmill.com
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via Chartmill · March 10, 2025
Top movers in Monday's pre-market sessionchartmill.com
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · March 10, 2025
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Outinvestors.com
The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment.
Via Investor's Business Daily · March 10, 2025
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · March 10, 2025